The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions
Open accessAbstract
Cancer's staggering molecular heterogeneity demands innovative approaches beyond traditional single-omics methods. The integration of multi-omics data, spanning genomics, transcriptomics, proteomics, metabolomics and radiomics, can improve diagnostic and prognostic accuracy when accompanied by rigorous preprocessing and external validation; for example, recent integrated classifiers report AUCs around 0.81-0.87 for difficult early-detection tasks. This review synthesizes how artificial intelligence (AI), particularly deep learning and machine learning, bridges this gap by enabling scalable, non-linear integration of disparate omics layers into clinically actionable insights. We explore cutting-edge AI methodologies, including graph neural networks for biological network modeling, transformers for cross-modal fusion, and explainable AI (XAI) for transparent clinical decision support. Critical applications are highlighted, such as AI-driven therapy selection (e.g., predicting targeted therapy resistance), proteogenomic early detection, and radiogenomic non-invasive diagnostics. We further address translational challenges: data harmonization, batch correction, missing data imputation, and computational scalability. Emerging trends, federated learning for privacy-preserving collaboration, spatial/single-cell omics for microenvironment decoding, quantum computing, and patient-centric "N-of-1" models, signal a paradigm shift toward dynamic, personalized cancer management. Despite persistent hurdles in model generalizability, ethical equity, and regulatory alignment, AI-powered multi-omics integration promises to transform precision oncology from reactive population-based approaches to proactive, individualized care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Integrated multi-omics classifiers consistently outperform single-modality models, with recent analyses reporting AUCs of 0.81–0.87 for early cancer detection using cross-omics feature integration”
From A generative AI multi-agent framework with integrated XAI governance for cancer diagnostics: from multi-omics interpretation to lifestyle risk stratification (2026) · cites this paper as Hsu et al., 2026
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Cancer Genome Atlas provides the most accessible resource for MO-XAI Agent validation, with comprehensive genomic and transcriptomic data for 33 cancer types linked to clinical outcomes (Hsu et al., 2026).”
From A generative AI multi-agent framework with integrated XAI governance for cancer diagnostics: from multi-omics interpretation to lifestyle risk stratification (2026) · cites this paper as Hsu et al., 2026
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FAIR Guiding Principles for scientific data management and stewardship
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.18 · Cited by 18,423 · cited 2×
“…directly affect whether AI-multiomics systems reach patients: (a) Interoperability & provenance: Use machine-readable metadata and standard schemas (FAIR; HL7 FHIR Genomics profiles) plus immu - table provenance logs so that data lineage and pre-analytical differences are auditable [ 61 , 62 ].”
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658 · cited 1×
“…(e.g., proteomics vs. tran - scriptomics, spatial vs. bulk), consider domain-adversarial encoders or conditional VAEs for domain-invariant repre - sentation learning, but also quantify residual batch signal (e.g., silhouette score by batch, variance explained by batch pre/post) [ 47 , 48].”
ComBat-seq: batch effect adjustment for RNA-seq count data
Zhang, Y., Parmigiani, G., & Johnson, W. E. (2020) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaa078 · Cited by 1,566 · cited 1×
“…(e.g., proteomics vs. tran - scriptomics, spatial vs. bulk), consider domain-adversarial encoders or conditional VAEs for domain-invariant repre - sentation learning, but also quantify residual batch signal (e.g., silhouette score by batch, variance explained by batch pre/post) [ 47 , 48].”
Deep learning-based multi-omics integration robustly predicts survival in liver cancer
Chaudhary, K., Poirion, O. B., Lu, L., & Garmire, L. X. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0853 · Cited by 1,091 · cited 1×
“…and provide candidate biomarkers, but they do not by themselves prove clinical utility, prospective interventional testing is still required [ 52]. steps, the federated model update schedule, and privacy-preserving mechanisms (e.g., differential privacy budget, homomorphic encryption)…”
Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., Reddy, K. R., Harnois, D., Llovet, J. M., Normolle, D., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.005 · Cited by 745 · cited 2×
“Recent HCC reviews and meta-analyses highlight the het - erogeneity of treatment response and the need for immune-aware stratification when selecting second-line therapies [ 51].”
Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23774-w · Cited by 671 · cited 3×
“…cohort studies, models like moGAT use atten - tion mechanisms to weight features from genomic, epig - enomic, and transcriptomic graphs, achieving an AUC of 0.92 in classifying cancer subtypes by effectively capturing the topological dependencies between molecular features [30, 32 , 33 ].”
InfluentialGenomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578 · cited 2×
“…should state (a) whether the model produced an actionable recommendation or was used only for stratification, (b) the prospective endpoint (e.g., ORR, PFS ratio, OS), (c) whether the decision was autonomous or MTB-mediated, and (d) performance on pre - specified fairness/subgroup metrics [ 53].”
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine
He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.009 · Cited by 445 · cited 6×
“Similarly, integrated omics classifiers have demonstrated robust diagnostic capabilities (AUC 0.81–0.87) for malignancies such as pancreatic can - cer where early detection remains challenging [ 17 , 22 ].”
InfluentialNavigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare
Mohr, A. E., Ortega-Santos, C. P., Whisner, C. M., Klein-Seetharaman, J., & Jasbi, P. (2024) · Biomedicines · doi:10.3390/biomedicines12071496 · Cited by 311 · cited 5×
“Recent implementa - tions leverage GNNs to model molecular interactions within tumor ecosystems, creating in silico simulations that predict individual responses to combination therapies [ 6 , 43].”
InfluentialDeep learning-based approaches for multi-omics data integration and analysis
Ballard, J. L., Wang, Z., Li, W., Shen, L., & Long, Q. (2024) · BioData Mining · doi:10.1186/s13040-024-00391-z · Cited by 258 · cited 6×
“The major trade-off for this enhanced power is their hunger for large sample sizes and substantial com - putational resources, making them prone to overfitting on rare cancer datasets without careful regularization [ 27 , 31].”
InfluentialArtificial intelligence assists precision medicine in cancer treatment
Liao, J., Li, X., Gan, Y., Han, S., Rong, P., Wang, W., Li, W., & Zhou, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.998222 · Cited by 256 · cited 1×
“…cancer, recent multi-center validations of combined proteomic + cfDNA panels reported high retrospective AUCs and promising prospec - tive pilot performance but continue to require randomized or prospective screening trials to show mortality benefit or clinically actionable lead-time [ 2 , 54].”
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J.-F., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 221 · cited 1×
“…represent cell–cell interaction graphs), spatial-transformer modules (to capture neighborhood context), or hybrid agent-based/mechanistic frameworks (to simulate recruitment and exhaustion dynamics) so as to predict immune evasion and treatment resistance in longitudinal cohorts [ 51 , 78 – 81].”
AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis
Alum, E. U. (2025) · Discover Oncology · doi:10.1007/s12672-025-02064-7 · Cited by 208
Current AI technologies in cancer diagnostics and treatment
Tiwari, A., Mishra, S., & Kuo, T.-R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02369-9 · Cited by 207
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
Lotter, W., Hassett, M. J., Schultz, N., Kehl, K. L., Van Allen, E. M., & Cerami, E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1199 · Cited by 196 · cited 1×
“Emerging solutions include the development of “fed - erated regulatory sandboxes” that permit provisional model validation under harmonized international guidelines [ 73].”
Fountzilas, E., Pearce, T., Baysal, M. A., Chakraborty, A., & Tsimberidou, A. M. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01471-y · Cited by 190 · cited 10×
“Immunotherapy has further intensified the need for multi-parameter biomarkers, where PD-L1 immunohistochemistry (IHC), tumor mutational burden (genomics), and T-cell receptor clonality (immunomics) collectively, but imperfectly, predict immune checkpoint blockade efficacy [ 1 , 6 ].”
InfluentialFerber, D., El Nahhas, O. S. M., Wölflein, G., Wiest, I. C., Clusmann, J., Leßmann, M.-E., Foersch, S., Lammert, J., Tschochohei, M., Jäger, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00991-6 · Cited by 175
Wekesa, J. S., & Kimwele, M. W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1199087 · Cited by 163 · cited 4×
“Population-specific genetic architectures, envi - ronmental exposures, and socioeconomic factors introduce confounding variations that are rarely accounted for in sin - gle-center studies [ 4 , 36 ].”
InfluentialWei, L., Niraula, D., Gates, E. D. H., Fu, J., Luo, Y., Nyflot, M. J., Bowen, S. R., El Naqa, I. M., & Cui, S. (2023) · The British Journal of Radiology · doi:10.1259/bjr.20230211 · Cited by 162 · cited 7×
“These limitations highlight a critical insight, cancer’s hallmark is not a single aberrant pathway but a dysregulated system of molecular networks, demanding commensurately multidi - mensional diagnostics [ 3 , 5].”
InfluentialA benchmark study of deep learning-based multi-omics data fusion methods for cancer
Leng, D., Zheng, L., Wen, Y., Zhang, Y., Wu, L., Wang, J., Wang, M., Zhang, Z., He, S., & Bo, X. (2022) · Genome Biology · doi:10.1186/s13059-022-02739-2 · Cited by 162 · cited 8×
“…cohort studies, models like moGAT use atten - tion mechanisms to weight features from genomic, epig - enomic, and transcriptomic graphs, achieving an AUC of 0.92 in classifying cancer subtypes by effectively capturing the topological dependencies between molecular features [30, 32 , 33 ].”
InfluentialAcharya, D., & Mukhopadhyay, A. (2024) · Briefings in Functional Genomics · doi:10.1093/bfgp/elae013 · Cited by 162 · cited 1×
“Dimensional dispari - ties range from millions of genetic variants to thousands of metabolites, creating a “curse of dimensionality” that neces - sitates sophisticated feature reduction techniques prior to integration [ 18 , 23 ].”
Shen, Y., Yu, J., Zhou, J., & Hu, G. (2024) · Journal of Medical Internet Research · doi:10.2196/59024 · Cited by 137 · cited 1×
“The ONCO-CAST system reduced time-to-trial-enrollment by 42% through automated matching of NTRK fusions and RET rearrangements documented in pathology reports with open targeted therapy trials [ 57 , 58 ].”
Assessing the Impact of Data Preprocessing on Analyzing Next Generation Sequencing Data
He, B., Zhu, R., Yang, H., Lu, Q., Wang, W., Song, L., Sun, X. J., Zhang, G., Li, S., Yang, J., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00817 · Cited by 134 · cited 1×
“Batch effects can introduce systematic biases that obscure biological signals and compromise downstream analyses, highlighting the critical importance of robust data preprocessing steps [ 41 ].”
Zhou, S., Wang, S., Wu, Q., Azim, R., & Wen, L. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107200 · Cited by 122 · cited 1×
“For instance, in leukemia subtyping, where decisions often rely on a concise set of clinical and cytogenetic features, GB models achieved 97% accuracy using only 17 features, providing clinicians with a transparent and actionable tool [ 27 , 28 ].”
Multiomics Research: Principles and Challenges in Integrated Analysis
Luo, Y., Zhao, C., & Chen, F. (2024) · BioDesign Research · doi:10.34133/bdr.0059 · Cited by 120 · cited 2×
“…persist, particularly regarding data standardization, compu - tational scalability, and clinical validation, recent advances in DL, autonomous AI systems, and spatial omics integra - tion provide robust frameworks for translating molecular complexity into therapeutic opportunity [ 18 , 24 , 25].”
Mao, Y., Shangguan, D., Huang, Q., Xiao, L., Cao, D., Zhou, H., & Wang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02321-x · Cited by 114 · cited 1×
“The HECTOR framework exemplifies this progress, integrating hematoxylin and eosin (H&E)-stained whole-slide images with molecular classification through a gating-based atten - tion mechanism, effectively harmonizing disparate data streams while minimizing technical variability [ 44].”
Demystifying the black box: A survey on explainable artificial intelligence (XAI) in bioinformatics
Budhkar, A., Song, Q., Su, J., & Zhang, X. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.12.027 · Cited by 107 · cited 3×
“For instance, SHAP analysis revealed that PHF11 and ZFP36 gene mutations contrib - ute 34% of the predictive variance in melanoma immuno - therapy response, guiding biologists to validate their roles in immune checkpoint regulation [ 38 , 39 ].”
Artificial intelligence for omics data analysis
Ahmed, Z., Wan, S., Zhang, F., & Zhong, W. (2024) · BMC Methods · doi:10.1186/s44330-024-00004-5 · Cited by 100 · cited 7×
“For instance, the OmicsNotator pipeline implements a decision tree that applies matrix factorization for batch-related missingness, DL for biologically relevant missingness, and flags samples exceeding predefined miss - ingness thresholds [50].”
InfluentialCremonesi, F., Planat, V., Kalokyri, V., Kondylakis, H., Sanavia, T., Resinas, V. M. M., Singh, B., & Uribe, S. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104338 · Cited by 86 · cited 3×
“The ONCO-CAST system reduced time-to-trial-enrollment by 42% through automated matching of NTRK fusions and RET rearrangements documented in pathology reports with open targeted therapy trials [ 57 , 58 ].”
InfluentialA Comprehensive Review of Deep Learning Applications with Multi-Omics Data in Cancer Research
Sartori, F., Codicè, F., Caranzano, I., Rollo, C., Birolo, G., Fariselli, P., & Pancotti, C. (2025) · Genes · doi:10.3390/genes16060648 · Cited by 85
Advancing precision oncology with AI-powered genomic analysis
Srivastava, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591696 · Cited by 84 · cited 2×
“Technical heterogeneity compounds this issue: batch effects from sequencing platforms (e.g., Illumina vs. Oxford Nanopore), sample processing protocols, and bioinformatic pipelines create spurious signals that AI models may erroneously learn as biologically significant [ 4 , 64].”
Ye, J., Lin, Y., Liao, Z., Gao, X., Lu, C. Y., Lu, L., Huang, J., Huang, X., Huang, S., Yu, H., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00752-1 · Cited by 84 · cited 4×
“Computational challenges remain substantial, as demonstrated by the HepatoSpa - tialDB initiative, where AI-driven alignment of 81,698 sin - gle-cell transcriptomes with 25,624 spatial spots required novel GNNs to resolve cellular interaction neighborhoods [ 75 ].”
InfluentialCheng, X., Peng, T., Chu, T., Yang, Y., Liu, J., Gao, Q., Cao, C., & Wei, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01722-1 · Cited by 82
Sen, P., & Orešič, M. (2023) · Metabolites · doi:10.3390/metabo13070855 · Cited by 80 · cited 6×
“Finally, metabolo - mics profiles small-molecule metabolites, the biochemical endpoints of cellular processes, using NMR spectroscopy and liquid chromatography–mass spectrometry (LC-MS), exposing metabolic reprogramming in tumors such as War - burg effects or oncometabolite accumulation [ 21 , 22 ].”
InfluentialWu, X., Fu, M., Ge, C., Zhou, H., Huang, H., Zhong, M., Zhang, M., Xu, H., Zhu, G., Hua, W., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-023-03911-w · Cited by 78 · cited 2×
“Transcriptomics reveals gene expression dynamics through RNA sequencing (RNA-seq), quantifying mRNA isoforms, non-coding RNAs, and fusion transcripts that reflect active transcriptional programs and regulatory networks within tumors [ 16 – 18].”
Current Bioinformatics Tools in Precision Oncology
Wolde, T., Bhardwaj, V., & Pandey, V. (2025) · MedComm · doi:10.1002/mco2.70243 · Cited by 78 · cited 7×
“…tasks across simulated, single-cell and TCGA cancer datasets, but it also high - lighted that no single architecture dominates every task prognostic signatures in lung adenocarcinoma (AFAP1L2, CAMK1D, LOXL2, PIK3CG) have enabled refined sur - vival prediction beyond conventional staging [ 14 ].”
InfluentialHu, F., Yang, H., Qiu, L., Wang, X., Ren, Z., Wei, S., Zhou, H., Chen, Y., & Hu, H. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1635475 · Cited by 76 · cited 2×
“Federated learning (FL) frameworks are revolutionizing multi-institutional collaboration by enabling model training on distributed omics datasets without centralizing sensitive patient information, a concept supported by innovations in digital health networks [ 59 ].”
Multi-omics data integration and analysis pipeline for precision medicine: Systematic review
Abdelaziz, E. H., Ismail, R. M., Mabrouk, M. S., & Amin, E. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108254 · Cited by 72 · cited 7×
“…from technical limitations (e.g., undetectable low-abundance proteins) and biological con - straints (e.g., tissue-specific metabolite expression), requir - ing advanced imputation strategies like matrix factorization or DL-based reconstruction to enable comprehensive analy - sis [ 18 , 21 ].”
InfluentialThe Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors
Li, X., Qu, J., Teng, X.-Q., Zhuang, H.-H., Dai, Y.-H., Yang, Z. G., & Qu, Q. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78535 · Cited by 71 · cited 1×
“…in gene expression not encoded within the DNA sequence itself, including DNA methylation patterns, histone modifications, and chroma - tin accessibility, which increasingly serve as diagnostic and prognostic biomarkers (e.g., MLH1 hypermethylation in microsatellite instability) [ 14 , 19 , 20].”
Artificial Intelligence–Driven Computational Approaches in the Development of Anticancer Drugs
Garg, P. K., Singhal, G., Kulkarni, P., Horne, D. A., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16223884 · Cited by 68 · cited 9×
“Recent algorithmic innovations focus on efficiency optimization, knowledge distillation tech - niques compress ensemble models into lightweight vari - ants with minimal accuracy loss, while federated learning reduces central computational loads [ 66 ].”
InfluentialSolimando, A. G., Susca, N., Argentiero, A., Brunetti, O., Leone, P., Re, V. D., Fasano, R., Krebs, M., Petracci, E., Azzali, I., et al. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00727-7 · Cited by 68
Yang, H., Zhou, H., Fu, M., Xu, H., Huang, H., Zhong, M., Zhang, M., Hua, W., Lv, K., & Zhu, G. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129332 · Cited by 62 · cited 1×
“Multi-modal transformers fuse MRI radiomics with tran - scriptomic data to predict glioma progression, revealing imaging correlates of hypoxia-related gene expression [ 5 , 9 , 13 ].”
Zhang, G., Song, C., Yin, M., Liu, L., Zhang, Y., Li, Y., Zhang, J., Guo, M., & Li, C. (2025) · Nature Communications · doi:10.1038/s41467-025-58921-0 · Cited by 58 · cited 1×
“…are powerful for genome-wide integration tasks and imputation, as they can model long-range depen - dencies across millions of genomic and transcriptomic fea - tures to infer missing proteomic data, thereby improving the accuracy of inferring traits like tumor clonality by 7–10% [ 31 , 36 , 37].”
Multi-omics data integration approaches for precision oncology
Aguila, R. C., Alonso-Pupo, N., & Hernández‐Rodríguez, E. W. (2022) · Molecular Omics · doi:10.1039/d1mo00411e · Cited by 57 · cited 2×
“Each layer provides orthogonal yet interconnected biological insights, collectively constructing a comprehensive molecu - lar atlas of malignancy [ 17 , 19 ].”
Far, B. F. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00160 · Cited by 56 · cited 2×
“…from integrated genomic and histopathology data Research Exchange (ORE), provides immutable audit trails documenting data lineage and access events across consor - tium members, enabling rapid breach containment while maintaining compliance with evolving regulations like the EU AI Act [ 7 , 63 ].”
A machine learning and deep learning-based integrated multi-omics technique for leukemia prediction
Abbasi, E. Y., Deng, Z., Arain, Q. A., Khan, A., Shaikh, A., Reshan, M. S. A., Sulaiman, A. A., & Alshahrani, H. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25369 · Cited by 56 · cited 2×
“The major trade-off for this enhanced power is their hunger for large sample sizes and substantial com - putational resources, making them prone to overfitting on rare cancer datasets without careful regularization [ 27 , 31].”
Multi-omics based artificial intelligence for cancer research
Li, L., Sun, M., Wang, J., & Wan, S. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.06.005 · Cited by 55 · cited 6×
“These limitations highlight a critical insight, cancer’s hallmark is not a single aberrant pathway but a dysregulated system of molecular networks, demanding commensurately multidi - mensional diagnostics [ 3 , 5].”
InfluentialZhang, S., Li, J., Zhang, Y., & Hu, X. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105096 · Cited by 55 · cited 1×
“…directly affect whether AI-multiomics systems reach patients: (a) Interoperability & provenance: Use machine-readable metadata and standard schemas (FAIR; HL7 FHIR Genomics profiles) plus immu - table provenance logs so that data lineage and pre-analytical differences are auditable [ 61 , 62 ].”
Camps, J., Jiménez-Franco, A., García-Pablo, R., Joven, J., & Arenas, M. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167841 · Cited by 55 · cited 3×
“…algorithm transparency, batch effect robustness, and ethical equity in data representation High dimensionality, batch effects, missing data [ 5 , 11] Phenotypic/clinical omics Radiomics, pathomics (digital pathology), hematological omics, electronic health records Non-invasive diagnosis, tumor…”
Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets
Raoufi, A., Samarkhazan, H. S., Nouri, S., Khaksari, M. N., Sourki, P. A., Sargazi-Aval, O., Baradaran, B., & Aghaei, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01588-0 · Cited by 54 · cited 1×
“Integrated analysis of hepatocellular carcinoma (HCC) ecosystems has identi - fied LGALS4+/MT1G + malignant subclones that drive immunosuppressive niches through metabolic coercion of tumor-associated macrophages (TAMs) [ 75 – 77].”
Network-based integration of multi-omics data for clinical outcome prediction in neuroblastoma
Wang, C., Lue, W., Kaalia, R., Kumar, P., & Rajapakse, J. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-19019-5 · Cited by 50 · cited 2×
“…cohort studies, models like moGAT use atten - tion mechanisms to weight features from genomic, epig - enomic, and transcriptomic graphs, achieving an AUC of 0.92 in classifying cancer subtypes by effectively capturing the topological dependencies between molecular features [30, 32 , 33 ].”
InfluentialMulti-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies
Salvati, A., Melone, V., Giordano, A., Lamberti, J., Palumbo, D., Palo, L., Rea, D., Memoli, D., Simonis, V., Alexandrova, E., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06856-x · Cited by 45 · cited 2×
“This issue is particularly pronounced for drug resistance pheno - types, where multi-omics profiles pre-and post-resistance development are rarely systematically biobanked [ 65].”
Li, J., He, H. G., Guan, C., Ding, Y., & Hu, X. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110993 · Cited by 45 · cited 1×
“…modeling asynchronous, variable-interval time-series data exceeds the capabilities of conventional AI architectures, leading to oversimplified representations of tumor evolution [ 69 ], though emerging models for specific toxicities like radione - crosis show the potential of this approach [70 ].”
Chen, Y., Li, L., Chen, X., Yan, Q., & Hu, X. (2025) · Worldviews on Evidence-Based Nursing · doi:10.1111/wvn.70048 · Cited by 43 · cited 1×
“Such cohorts permit measure - ment of calibration drift, real-world deployment constraints, and model generalizability before a randomized trial is attempted [ 55 , 56 , 60 ].”
Lu, Y., Peng, R., Dong, L., Xia, K., Wu, R., Xu, S., & Wang, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad378 · Cited by 39 · cited 2×
“powered by sophisticated AI-driven integration tools [ 9 , 10 ].”
DeePathNet: A Transformer-Based Deep Learning Model Integrating Multiomic Data with Cancer Pathways
Cai, Z., Poulos, R. C., Aref, A., Robinson, P. J., Reddel, R. R., & Zhong, Q. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0285 · Cited by 36
You, C., Su, G.-H., Zhang, X., Xiao, Y., Zheng, R., Sun, S., Zhou, J.-Y., Lin, L., Wang, Z., Wang, H., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00666-y · Cited by 35 · cited 2×
“Such cohorts permit measure - ment of calibration drift, real-world deployment constraints, and model generalizability before a randomized trial is attempted [ 55 , 56 , 60 ].”
Shao, Y., Lv, X.-Y., Ying, S., & Guo, Q. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2912404 · Cited by 34 · cited 4×
“Federated learning has emerged as a promising technical solution: The HARMONY + consortium demonstrated secure training of a DLBCL survival predictor across 37 institutions, maintaining model performance within 2% of centralized training while pre - venting raw data egress [ 7 ].”
InfluentialFrom Genomics to AI: Revolutionizing Precision Medicine in Oncology
Calvino, G., Farro, J., Zampatti, S., Peconi, C., Megalizzi, D., Trastulli, G., Andreucci, S., Cascella, R., Strafella, C., Caltagirone, C., et al. (2025) · Applied Sciences · doi:10.3390/app15126578 · Cited by 33 · cited 3×
“Velocity demands rapid integration of real-time data streams, such as continuous monitoring of ctDNA during therapy [ 2 , 8 ].”
Bongurala, A. R., Save, D., & Virmani, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1533910 · Cited by 32 · cited 4×
“Autonomous AI agents now process patient-generated health data from wearables and home biosensors, detecting cytokine release syndromes 48 h before clinical manifes - tation via subtle metabolomic shifts in sweat biomarkers (IL-6 correlation: r = 0.89) [ 72 , 84 ].”
InfluentialSamarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01858-x · Cited by 29 · cited 1×
“…IG identified cryptic epigenomic markers (e.g., H3K27ac peaks) that modulate chemotherapy resis - tance, corroborated by ChIP-seq assays [ 31 , 38 , 40 ]. retained vs. batch covariates removed), whether parametric or non-parametric adjustments were used, and include diag - nostic plots (PCA/UMAP…”
Liu, Z., & Park, T. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1488683 · Cited by 27
Hounye, A. H., Xiong, L., & Hou, M. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02050-4 · Cited by 26 · cited 3×
“For instance, SHAP analysis revealed that PHF11 and ZFP36 gene mutations contrib - ute 34% of the predictive variance in melanoma immuno - therapy response, guiding biologists to validate their roles in immune checkpoint regulation [ 38 , 39 ].”
Application of spatial and single-cell omics in tumor immunotherapy biomarkers
Zhang, C., Feng, H.-R., Zhu, J., & Hong, W. (2025) · LabMed discovery. · doi:10.1016/j.lmd.2025.100076 · Cited by 22
Targeting platelet-tumor cell interactions: a novel approach to cancer therapy
Rab, S. O., Altalbawy, F. M. A., Bishoyi, A. K., Ballal, S., Kareem, M. A., Singh, A., Kubaev, A., Samarkhazan, H. S., & Bagheri, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02787-1 · Cited by 22
Matarèse, B. F. E., & Purushotham, A. D. (2025) · Quantum Reports · doi:10.3390/quantum7010009 · Cited by 21
A review of AI-based radiogenomics in neurodegenerative disease
Liu, H., Zhang, X., & Liu, Q. (2025) · Frontiers in Big Data · doi:10.3389/fdata.2025.1515341 · Cited by 17 · cited 1×
“While techniques such as semi-supervised learning and positive-unlabeled learning show promise in leveraging unannotated data, they often fail to capture nuanced clinical phenotypes defined by multi-system interactions [ 67 ].”
Ancillotti, M., Grauman, Å., Veldwijk, J., Flobak, Å., & Mascalzoni, D. (2025) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-025-03134-0 · Cited by 11 · cited 4×
“…exponential acceleration of currently intractable multi-omics analyses through spe - cialized algorithms that harness quantum superposition 1 3 populations, transparent validation, and feasible implemen - tation pathways. decision pathways as interactive molecular interaction maps [ 71 , 84 ].”
InfluentialMolecular-based precision oncology clinical decision making augmented by artificial intelligence
Zeng, J., & Shufean, M. A. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210220 · Cited by 11 · cited 1×
“Genomic variant interpretation platforms such as OncoKB and IntO - Gen, enhanced by natural language processing for literature mining, annotate the therapeutic actionability of mutations while predicting resistance mechanisms [ 15 , 26 ].”
El‐Deiry, W. S., Bresson, C., Wunder, F., Carneiro, B. A., Dizon, D. S., Warner, J. L., Graff, S. L., Azzoli, C. G., Wong, E. T., Liang Cheng, C., et al. (2025) · Oncotarget · doi:10.18632/oncotarget.28703 · Cited by 9 · cited 4×
“The RESPONS-AI framework addresses this through coun - terfactual explanation generators that visualize therapeutic multi-omic biomarkers across 32 countries, demonstrating 22% faster target therapy matching for rare cancer subtypes [ 74].”
InfluentialIqbal, Z., Alnuaim, L., Al-Garni, A., Alanzazi, N., AlMukhaylid, S., Qahtani, S. A., Shammas, M. A., Naeem, R. C., Taleb, Y. S., Karrar, T., et al. (2025) · medRxiv · doi:10.1101/2025.07.29.25332402 · Cited by 9 · cited 3×
“Similarly, integrated omics classifiers have demonstrated robust diagnostic capabilities (AUC 0.81–0.87) for malignancies such as pancreatic can - cer where early detection remains challenging [ 17 , 22 ].”
InfluentialQuantum Oncology: The Applications of Quantum Computing in Cancer Research
Li, J., Li, L., Liu, N., Xu, F., Hu, T., & Yuan, S. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02215-x · Cited by 8 · cited 7×
“The Quantum-HyperFold consortium is developing specialized quantum biosensors using nitro - gen-vacancy centers in diamonds that detect single-mole - cule protein interactions, potentially enabling liquid biopsy detection limits below 10 − 18 [ 82].”
InfluentialThe Role of Artificial Intelligence in Diagnosing Malignant Tumors
Ahmad, S., Khan, Z., Khan, M., Aijaz, M., Thakur, S., & Kamboj, A. (2024) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2024.24486 · Cited by 4
Self-citationPark, Y., Park, S., & EunJeong, B. (2025) · medRxiv · doi:10.1101/2025.07.12.25331423 · Cited by 1
Integrative Analysis of Differentially Expressed Genes in Time-Course Multi-Omics Data withMINT-DEPreprint
Xue, H., Delbare, S., Wells, M. T., Basu, S., & Clark, A. G. (2023) · Research Square · doi:10.21203/rs.3.rs-3806701/v1 · Cited by 1
Research works printed but not linked: 10
- Camps J, et al. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167841. · DOI
- Shmmon, Ahmad (2024) The Role of Artificial Intelligence in Diagnosing Malignant Tumors Eurasian Journal of Medicine and Oncology 281-294 10.14744/ejmo.2024.24486 · DOI
- Cai Z et al. Transformer-based deep learning integrates multi-omic data with cancer pathways. bioRxiv, 2024: p. 2022.10.27.514141. · DOI · Paper page
- Mohr AE, et al. Navigating challenges and opportunities in Multi-Omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496. · DOI · Paper page
- Sartori F et al. A comprehensive review of deep learning applications with Multi-Omics data in cancer research. Genes (Basel), 2025. 16(6). · DOI
- Shao Y, et al. Artificial Intelligence-Driven precision medicine: Multi-Omics and Spatial Multi-Omics approaches in diffuse large B-Cell lymphoma (DLBCL). Front Biosci (Landmark Ed). 2024;29(12):404. · DOI
- Mattei P-A, Frellsen J. MIWAE: Deep Generative Modelling and Imputation of Incomplete Data Sets. in International Conference on Machine Learning. 2019.
- Palmer DC, et al. GEMINI-NSCLC study: integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2025;43(16suppl):TPS8114–8114.
- Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol. 2025;16:1591696. · DOI
- Ferber D, et al. Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology. Nat Cancer. 2025;6(8):1337–49. · DOI · Paper page
Cited by
AbdelHamid, S. G., Halawa, E. M., Ibrahim, E., & ElHefnawi, M. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04263-w · Cited by 25
Fawzy, M. P., Nafie, M. S., Nabih, N. W., Diab, M. K., Babker, A. M. A., Mohamed, H., Hassan, H. A. F. M., & Fahmy, S. A. (2026) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2026.100168 · Cited by 17
Darzi, A., Shokouhfar, M., Farajee, N., Ghafari, A., Deldar, F., Eini, P., Vanan, A. G., & Bahrami, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118875 · Cited by 15
Deep Learning-Enabled Multi-Omics Integration: A New Frontier in Precise Drug Target Discovery
Ren, Y., Bai, H., Wang, J., Yang, Y., & Wang, Y. (2026) · Biology · doi:10.3390/biology15050410 · Cited by 18
“To bridge this divide, the field must pivot from correlation-based learning toward causality-aware XAI frameworks [140,141].”
Omics medicine: what the clinicians should know
Zamperla, M. G., Barbi, V., Negri, S., Atlante, S., & Gaetano, C. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106759 · Cited by 14
Metadata
- Authors
- Hsu, C.-Y., Askar, S., Alshkarchy, S. S., Nayak, P. P., Attabi, K. A. L., Khan, M. A., Mayan, J. A., Sharma, M. K., Islomov, S., & Soleimani Samarkhazan, H.
- Affiliations
- Chia Nan University of Pharmacy and Science (TW)
- Erbil Polytechnic University (IQ)
- Al-Qasim Green University (IQ)
- Siksha O Anusandhan University (IN)
- Islamic University of Najaf (IQ)
- Dhofar University (OM)
- Sathyabama Institute of Science and Technology (IN)
- Chaudhary Charan Singh University (IN)
- ORCID
- Venue
- Clinical and Experimental Medicine
- Published
- 2025-11-21
- Volume
- 26
- Issue
- 1
- Pages
- 29-29
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- PMC
- PMC12634751
- OpenAlex
- W4416442660
- Cited by
- 140
- References
- 74
- Citations by year
- 2026: 136 · 2025: 4
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- multi-omics integration, precision oncology, artificial intelligence in oncology, deep learning, graph neural networks, transformer models, cross-modal fusion, explainable AI, clinical decision support, radiogenomics, non-invasive cancer diagnosis, data harmonization, batch effect correction, missing data imputation, federated learning, single-cell omics, tumor microenvironment, quantum computing, model generalization
- MeSH terms
- Clinical Decision-Making, Machine Learning, Deep Learning, Multiomics, Artificial Intelligence, Humans, Medical Oncology, Neoplasms, Genomics, Proteomics, Metabolomics, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.